Krystal Biotech KRYS Q2 2026: Misses Estimates but VYJUVEK Keeps Growing
As seen on the 24/7 Wall St. homepage on August 3, 2026.
Krystal Biotech missed Q2 on both lines, but VYJUVEK's 24% revenue growth and a slate of pipeline readouts coming in the next 12 to 18 months signal the gene therapy company is ready to transition from single-product star to multi-product powerhouse.
Continue ReadingShow less
Krystal Biotech reported Q2 2026 revenue of $119.2 million, coming in about 1.5% below the consensus estimate of $121 million. Earnings per share of $1.79 also fell short, trailing the $1.91 estimate by roughly 6.5%. Despite the dual miss, the quarterly result still represents meaningful sequential and year-over-year progress — revenue has climbed from $70.3 million in Q2 2024 to $119.2 million in the most recent quarter, a steady upward trajectory across nine consecutive periods.
The growth engine behind those numbers is VYJUVEK, the company's approved gene therapy, which posted 24% revenue growth during the quarter. That kind of commercial momentum matters for a biotech that has so far depended almost entirely on a single product, and it gives Krystal a stronger financial foundation as it looks to broaden its portfolio.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
What investors will be watching most closely is the pipeline. Krystal has flagged a slate of readouts expected over the next 12 to 18 months, which the company frames as its path from a single-product story to a multi-product gene therapy platform. How those data points land will go a long way toward determining whether the current revenue trend can continue to accelerate.
Mentioned: KRYS